General discussion, page-566

Impression Healthcare Limited (ASX:IHL)
Cannabinoid medicines development company Impression Healthcare Limited is into developing unique treatment of traumatic brain injury, obstructive sleep apnoea, temporomandibular joint disorder and acute respiratory distress syndrome (ARDS).
Commencement of Animal Study for Evaluating IHL-675A Against ARDS
On 2 June 2020, Impression Healthcare disclosed the beginning of its first animal study for SAARDS (sepsis-associated acute respiratory distress syndrome) program, SAARDS is a leading cause of death due to COVID-19 as well as other infections like lung, stomach, skin, and kidney infections.
The animal study shall assess the mode of action of IHL-675A for inflammation reduction by evaluating levels of cytokine subsequent the induction of sepsis.
Moreover, the next stage of the study will consist of the investigation of specific combinations of Cannabidiol and Hydroxychloroquine, employing the learnings of the earlier stage, to examine the optimal inflammation inhibiting the response of the IHL-675A combination drug.
Notably, with this step, Impression Healthcare is assured that it will drive value for its stakeholders.
COVID-19 RELATED: Mysterious Threat of Antimicrobial Resistance Behind COVID-19
A Surge in Cannabinoid Product Sales
Impression Healthcare updated the market that the Company will discontinue the sale of oral devices from 30 June 2020 and shall entirely focus on its resources on cannabinoid sales and some other development activities.
Despite the diminished sale of oral devices, IHL foresees its revenue for the ongoing quarter to be markedly greater than the previous corresponding period due to the advantage of significantly increasing cannabinoid formulations sales.
Four cannabinoid clinical development programs of Impression are underway for the complications having no existing registered treatment options currently available: